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Purpose. To evaluate and compare autocrine expression and production of interleukin-6 (IL-6), a pleiotropic cytokine involved in the
resistance to cytotoxic agents and inhibition of anti-tumor immune function in endometrial carcinoma in vitro as well as in vivo.
Patients and methods. IL-6 gene expression levels were evaluated in twenty-four primary endometrial tumors including 14 endometrioid
carcinomas (EC) and 10 uterine serous papillary carcinoma (USPC) as well as in normal control endometrial cells (NEC) by real-time PCR.
Secretion of IL-6 protein by 6 primary endometrial tumor cultures including USPC and EC was measured using a sensitive enzyme-linked
immunosorbent assay (ELISA) in vitro. Finally, IL-6 concentration in 71 serum samples including 20 apparently healthy women, 19 women
with benign abdominal diseases, 19 women with primary EC, and 13 USPC patients was studied.
Results. IL-6 gene expression levels were significantly higher in USPC when compared to EC (mean copy number by RT-PCR = 313 T
55 vs. 53 T 11, USPC vs. EC, respectively: P < 0.01). IL-6 serum concentrations between normal healthy females (range 0.01–21.23 pg/ml;
mean 3.1 pg/ml) and benign disease patients (range 0.01–95.77 pg/ml; mean 13.07 pg/ml) were not statistically different. In contrast,
significantly higher levels of IL-6 were detected in both patients with EC (range 2.86–82.13 pg/ml; mean 20.43 pg/ml) and patients with
UPSC (range 16.3–500.1 pg/ml; mean 125.7 pg/ml) when compared to the healthy females (P < 0.01), with a mean serum IL-6 level in
USPC patients 6.1-fold higher when compared to EC patients (P < 0.03). Accordingly, higher levels of IL-6 secretion were noted in primary
USPC cell lines (mean 3121 pg/ml, range between 1099 and 5017 pg/ml/105 cells/48 h) when compared to primary EC (mean 88, range
between 19 and 112 pg/ml/105 cells/48 h) (P < 0.01) in vitro.
Conclusions. IL-6 is highly expressed in USPC, and it is released in high concentration in the serum of USPC patients. IL-6 may be a
novel biomarker for USPC. Drugs used to inhibit the expression of IL-6 or the IL-6 signal transduction pathway may potentially be highly
beneficial in USPC.
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Endometrial carcinoma is the most prevalent gynecologic
tumor in women, with an estimated 40,320 cases and 7090
deaths in the United States in 2004 [1]. On the basis of
clinical and histopathologic variables, two subtypes of
endometrial carcinoma, namely Type I and Type II tumors,
have been described [2]. Type I endometrial cancers account98 (2005) 92 – 98
Table 1
Characteristics of the patients from which primary tumor biopsies were
obtained
NEC n = 3 EC n = 14 USPC n = 10
Age (mean T SD) 49 T 3 58 T 11 63 T 10
Stage
I – 11 1
II – 2 1
III – 1 5
IV – – 3
Grading
G1 – 8 –
G2 – 4 –
G3 – 2 10
NEC = normal endometrial cells.
EC = endometrial cancer.
USPC = uterine serous papillary carcinoma.
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associated with a history of hyperestrogenism as the main
risk factor, are well or moderately differentiated in their
histology, and typically have a favorable prognosis with
appropriate therapy. In contrast, Type II endometrial cancers
are poorly differentiated tumors, often with serous papillary
or clear cell histology and are not associated with hyper-
estrogenic factors. These tumors are biologically highly
aggressive and account for about 50% of all relapses which
occur in endometrial cancer patients [2,3].
Uterine serous papillary carcinoma (USPC) represents the
most aggressive variant of Type II endometrial cancer and
may constitute up to 10% of endometrial tumors [4–11]. The
microscopic criteria for diagnosis of USPCwere first outlined
by Hendrickson in 1982 [11]. Typically, the neoplastic
epithelium is characterized by serous differentiation with
psammoma bodies present and with predominantly papillary
architecture [11]. Pleomorphism, grade III nuclear atypia
with prominent nucleoli and a vesicular chromatin pattern, as
well as a high mitotic activity are commonly detected in this
tumor. Clinically, USPC has a propensity for early intra-
abdominal and lymphatic spread even at presentation and is
characterized by a highly aggressive biologic behavior [4–
11]. Unlike the histologically similar high grade serous
ovarian carcinomas, USPC is a chemoresistant disease from
onset, with responses to combined cisplatinum-based chemo-
therapy in the order of 20% and of short duration [7–9]. The
survival rate is dismal, even when USPC is only a minor
component of the histologically more common endometrioid
adenocarcinoma, and widespread metastasis and high mortal-
ity may occur even in those cases in which tumor is confined
to the endometrium or to an endometrial polyp [4–11]. The
overall 5-year survival is about 30% for all stages and the
recurrence rate after surgery is extremely high (50% to 80%).
The discovery of novel diagnostic and therapeutic markers
against this aggressive subset of endometrial cancers remains
a high priority.
With the goal of identifying genes highly and differ-
entially expressed in USPC and to use this knowledge for the
development of novel diagnostic and therapeutic markers
against this disease, our group has recently used high-
throughput technologies, such as high-density oligonucleo-
tide microarrays to analyze USPC genetic fingerprints [12].
Among the several candidate target genes identified, the
gene encoding for human interleukin-6 (IL-6) was consis-
tently found as one of the most highly up-regulated genes in
USPC. In this regard, IL-6 is a pleiotropic cytokine endowed
with a variety of effects on hematopoiesis, the immune
system, and acute-phase responses [13]. IL-6 has been
previously shown to regulate cell growth of a variety of
human cancers, and high serum levels of this cytokine have
been correlated with shorter survival in patients harboring
renal carcinoma, prostate cancer, and ovarian carcinoma
[14–17]. Recently, autocrine secretion of IL-6 in cholangio-
carcinoma and breast human tumors has been correlated with
an altered expression of apoptosis regulatory proteinscausing high resistance of these tumors to chemotherapy
[18,19]. Because of these intriguing observations and the fact
that no studies have investigated autocrine production of IL-
6 in USPC, a highly aggressive and chemotherapy-resistant
variant of endometrial cancer, in this study, we have carefully
investigated IL-6 gene expression and protein secretion in
Type I (i.e., endometrioid) and Type II (i.e., USPC)
endometrial cancer in vitro as well as in vivo.Patients and methods
Primary tumors
Tumor samples were derived from primary specimens
staged according to the F.I.G.O. operative staging system.
Fresh tumor biopsies from twenty-four endometrial tumors
including 14 EC and 10 USPC were derived from patients
harboring invasive tumors at the time of surgery through the
Gynecologic Oncology Division and the Pathology Depart-
ment, UAMS, under approval of the Institutional Review
Board. Patient characteristics from which tumor biopsies
were obtained are described in Table 1. Total abdominal
hysterectomy and bilateral lymph node dissection were
performed in all endometrial cancer patients. Three normal
endometrial control cell samples (NEC) were obtained from
biopsies of benign hysterectomy specimens from similar age
women. Primary tumor samples and NECwere established as
short-term cultures following previously reported standard
tissue culture techniques [12,20]. Briefly, normal tissue
obtained from healthy endometria and tumor tissues obtained
from cancer patients were mechanically minced and enzy-
matically dissociated with 0.14% collagenase Type I (Sigma,
St. Louis, MO) in RPMI 1640 medium (Invitrogen, Grand
Island, NY) as described previously by Bongso et al., with
minor modifications [20], and Santin et al. [12,21]. After 1–2
h incubation with enzyme on a magnetic stirring apparatus at
37-C in an atmosphere of 5% CO2, the resulting suspension
Table 2












(mean T SD) 42.6 T 10.9 46.2 T 15.6 62.9 T 11.3 68.2 T 9.5
Stage
I – – 14 1
II – – 3 1
III – – 2 7
IV – – – 4
Grading
G1 – – 11 –
G2 – – 6 –
G3 – – 2 13
EC = endometrial cancer.
USPC = uterine serous papillary carcinoma.
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washed twice with RPMI 1640 medium containing 10% fetal
bovine serum (FBS, Invitrogen, Grand Island, NY). The final
pellet was then placed in RPMI 1640 containing 10% FBS,
200 u/ml penicillin, and 200 Ag/ml streptomycin in tissue
culture flasks or Petri dishes (Invitrogen). The epithelial
explants and tumor cells were then allowed to attach and
proliferate. Explants were trypsinized and subcultured for 1
to 2 passages before being collected for RNA extraction
while tumor cells were collected for RNA extraction at a
confluence of 50% to 80% after a minimum of two to a
maximum of ten passages in vitro. The epithelial nature and
the purity of tissue cultures were verified by immunohis-
tochemical staining and flow cytometric analysis with
antibodies against cytokeratin and vimentin as previously
described [12,20,21]. Only primary cultures which had at
least 90% viability and contained >99% epithelial cells
were used for IL-6 quantification by real-time PCR and
analyzed for IL-6 secretion in vitro by ELISA as described
below.
RNA isolation
RNA isolation from all primary samples including twenty-
four primary endometrial cancers (i.e., 10 USPC and 14 EC)
as well as 3 normal endometrial cell controls was performed
using TRIzol Reagent (Invitrogen) according to the manu-
facturer’s instructions. To verify integrity, 4 Ag of RNA from
each sample was run in 1% agarose gel using 18S+28S
ribosomal RNA (Sigma) as a positive control. RNA extracted
from CaOV3 serous papillary ovarian cancer cell line,
previously reported to express IL-6 [22], was used as a
positive control.
Quantitative real-time PCR
q-RT-PCR was performed with an ABI Prism 7000
Sequence Analyzer using the manufacturer’s recommended
protocol (Applied Biosystems, Foster City, CA) to evaluate
expression of IL-6 gene in samples from all primary cell
lines. Each reaction was run in triplicate. The comparative
threshold cycle (CT) method (PE Applied Biosystems) was
used to determine gene expression in each sample relative to
the value observed in the nonmalignant endometrial epithelial
cells, using GAPDH (Assay-on-Demand Hs99999905_m1)
RNA as an internal control. Briefly, 5 Ag of total RNA from
each sample was reverse-transcribed using SuperScript III
first strand cDNA synthesis (Invitrogen, Carlsbad, CA). Ten
microliters of reverse-transcribed RNA samples (from 500 Al
of total volume) were amplified by using the TaqMan
Universal PCRMaster Mix (Applied Biosystems) to produce
PCR products specific for IL-6. IL-6 primers were obtained
from Applied Biosystems as assay on demand products
(Assay ID: Hs00174131_m1). Differences among NEC,
USPC, and EC in the q-RT-PCR expression data were tested
using a Student’s t test.Analysis of IL-6 secretion
An important issue is whether differences in IL-6 gene
expression level in tumor tissues result in meaningful
differences in protein expression. To validate IL-6 data
obtained by RT-PCR on primary USPC and EC cell lines at
the protein level, supernatants obtained from 6 primary
endometrial specimens including 3 USPC and 3 EC were
evaluated by ELISA. Briefly, tumor supernatants tested for
IL-6 secretion were collected from primary cell lines seeded
at a density of 1  105 cells/ml in tissue culture Petri dishes
(Gibco) in RPMI 1640, supplemented with 10% FBS
(i.e., USPC and EC). After a 48 h incubation at 37-C,
supernatants were aspirated, rendered cell-free by centri-
fugation at 1500 rpm for 10 min, and stored at 80-C
before being analyzed for IL-6 by ELISA (R&D Systems
Inc. Minneapolis, MN).
IL-6 concentration was quantified in the serum of 20
apparently healthy women (ages 26 to 72 years; mean 43
years), 19 women with benign diseases (ages 21 to 76
years; mean 46 years), 19 women with histologically
proven primary endometrioid adenocarcinoma (ages 49 to
79 years; mean 63 years), and 13 women with histologi-
cally proven primary USPC (ages 53 to 84 years; mean 68
years) by ELISA. This assay has a detection limit of 3.12
pg/ml and a dynamic range up to 300 pg/ml. Of the benign
lesions, 12 were classified as endometriosis, 2 as mucinous
cystadenomas, 2 as ovarian dermoid cysts, 1 as ovarian
benign teratomas, 1 as corpus luteum, and 1 as serous
cystadenomas. The characteristics of the patients from
which serum samples were obtained are described in Table
2. Serum samples from all patients were collected before
surgery and stored at 80-C until analysis.
Statistical analysis
The analyses of differences between IL-6 serum con-
centrations among the different groups of patients (i.e.,
S. Bellone et al. / Gynecologic Oncology 98 (2005) 92–98 95healthy controls, benign gynecologic diseases, EC, and
USPC) as well as among USPC, EC, and NEC specimens in
the q-RT-PCR expression data were performed using the
Student’s t test at alpha = 0.05.Results
IL-6 expression in endometrial cancer by quantitative
real-time PCR
Tumor tissue flash frozen biopsies are known to contain
significant numbers of contaminant stromal cells as well as
a variety of host derived immune cells (e.g., monocytes,
dendritic cells, lymphocytes). In addition, USPC represents
rare tumors which may present in either pure forms or
admixed with endometrioid or clear cell tumor cells (i.e.,
mixed USPC) [4–11]. To minimize the risk of contami-
nation of USPC RNA with that of normal cells or tumor
cells with different histology, we extracted RNA to be
evaluated for IL-6 expression by RT-PCR from twenty-four
primary endometrial cancers with single type differentiation
(i.e., 10 USPC and 14 EC). Normal endometrial cell (NEC)
IL-6 levels from 3 samples were used as controls. Short
term USPC, EC, and NEC cell cultures, minimizing the risk
of a selection bias inherent in any long-term in vitro
growth, may provide an opportunity to study differential
gene expression between highly enriched populations of
normal and tumor-derived epithelial cells. A comparison of
the q-RT-PCR data for IL-6 in USPC and EC using NEC asFig. 1. IL-6 mRNA copy number by quantitative RT-PCR in 24 Type I and Type II
endometrial control cell samples (NEC), 14 endometrioid carcinoma (EC), and 10 u
individual NEC controls and Type I and Type II endometrial cancers.controls is shown in Fig. 1. Significant expression differ-
ences between USPC and EC were readily apparent (Figs.
1A and B). All USPC samples (10 out of 10 = 100%, mean
copy number T SEM = 313 T 55 range from 56 to 553) and
the majority of EC samples (11 out of 14 = 79%, mean
copy number T SEM = 53 T 11 range from 4 to 119) were
found positive for IL-6 expression by RT-PCR (Fig. 1B).
However, only 2 out of 14 of the EC (14%) had an mRNA
copy number above 105 (Fig. 1B). In contrast, 8 out of 10
USPC (80%) were found to highly express the IL-6 gene
(Fig. 1B, USPC vs. EC: P < 0.01). Low levels of IL-6 gene
expression were found in the NEC control cultures tested
(mean copy number T SEM = 5 T 2 range 1–9) (Fig. 1).
IL-6 secretion by primary Type I and Type II endometrial
cancer in vitro
Cell free supernatants from 6 freshly isolated endo-
metrial specimens including 3 USPC and 3 EC were
collected and analyzed for levels of IL-6 expression by
ELISA. Because prolonged passages in vitro are known
to alter the physiology and phenotype of primary tumor
cells, we performed all of our experiments with highly
purified fresh tumor cells grown for less than 10 passages
in vitro. Growth control medium was always analyzed at
the same time. In this regard, RPMI 1640 containing 10%
fetal bovine serum had no detectable endogenous levels
of IL-6 activity (data not shown). As shown in Fig. 2,
primary USPC tumor cell lines tested secreted large amounts
of IL-6 (range of secretion from 1099 to 5017 pg/ml/105endometrial cancers. (A) IL-6 mRNA mean copy number T SD in 3 normal
terine serous papillary carcinoma (USPC). (B) IL-6 mRNA copy number in
Fig. 2. IL-6 levels by ELISA in the supernatants from 6 primary short-term
endometrial tumor cultures including 3 USPC and 3 EC.
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were significantly higher when compared to EC cell lines
(range of secretion from 19 to 112 pg/ml/105 cells/48 h,
mean 88 pg/ml) (P < 0.01).
Serum IL-6 concentration in endometrial cancer and
noncancer patients
To investigate whether IL-6 is detectable in the serum of
patients harboring Type I and Type II endometrial cancer,
serum samples from 19 EC patients and 13 USPC patients
were evaluated by ELISA. In addition, serum samples
obtained from 20 healthy female controls and 19 patients
diagnosed with benign gynecologic diseases were analyzed
at the same time. IL-6 serum levels from 20 healthy female
controls (range 0.01–21.23 pg/ml; mean 3.05 pg/ml) and 19
patients with benign gynecologic diseases (range 0.01–
95.77 pg/ml; mean 13.07 pg/ml) were not statistically
significantly different (Table 3). In contrast, serum IL-6
values in patients with EC (range 2.86–82.13 pg/ml; mean
20.43 pg/ml) and USPC patients (range 16.3–500.1 pg/ml;
mean 125.7 pg/ml) were significantly higher than those in
the healthy group (P < 0.01). When IL-6 levels in the serum
of USPC patients were compared to the levels found in EC
patients, a significant difference was found with a mean
serum IL-6 level in USPC patients 6.1-fold higher when
compared to EC patients (P < 0.03).Table 3
Serum IL-6 in noncancer (healthy), benign disease, EC, and USPC patients
Variable mean T SEM Range (pg/ml)
Noncancer (n = 20) 3.1 T 1.1 0.01–21.23
Benign disease (n = 19) 13.07 T 4.9 0.01–95.77
EC (n = 19) 20.43 T 6.1 2.86–82.13
USPC (n = 13) 125.7 T 44.2* 16.3–500.1
* Noncancer vs. benign = P not significant; noncancer cells vs. EC = P >
0.01; noncancer vs. USPC = P > 0.01. Benign vs. EC = P not significant;
benign vs. USPC = P > 0.02. EC vs. USPC = P > 0.03.Discussion
This report represents the first evaluation of IL-6, a
pleiotropic cytokine previously associated with increased
resistance to chemotherapy, apoptosis, and inhibition of
anti-tumor immune function in a variety of human tumors
[13–19], as a novel biomarker in USPC patients. In this
study, we have quantified IL-6 expression by RT-PCR in
24 primary endometrial carcinomas including 14 EC and
10 USPC. In addition, we have studied IL-6 protein
secretion in 6 primary endometrial tumor specimens
including EC and USPC. In our study, we have confirmed
the purity of the tumor cells in fresh tumor specimens by
differential counts of Giemsa-stained cytospin slides as
well as by cytokeratin expression using immunohistochem-ical techniques (data not shown). Our fresh tumor samples
contained over 99% tumor cells. Finally, we have studied
IL-6 levels in 71 serum samples derived from healthy
donors, patients harboring benign gynecologic tumors, EC,
and USPC.
We report a high level of expression of the IL-6 gene in
USPC, a highly aggressive variant of uterine cancer. In
addition, we show that IL-6 gene expression is significantly
higher in USPC when compared to EC and NEC by RT-
PCR. In this regard, the mean copy number of IL-6 gene in
USPC was found to be 5.9 times higher when compared to
EC cells. Consistent with the gene expression results,
primary USPC cultures were found to secrete significantly
higher levels of IL-6 by ELISA when compared to primary
endometrioid carcinomas. These data highlight for the first
time a major difference between EC and USPC in the
expression and secretion of IL-6.
Importantly, recent reports have shown autocrine
production of IL-6 by human tumor cells to alter the
expression of apoptosis regulatory proteins [18] and cause
resistance of the tumors to chemotherapy [19]. These data,
demonstrating a novel mechanism of IL-6 to promote
tumor cell survival, have highlighted the potential of IL-6
as a prognostic indicator for the identification of cancers
highly resistant to chemotherapy. In agreement with these
data, elevated serum levels of IL-6 in a subset of ovarian
cancer patients harboring serous papillary ovarian tumors,
a variant of ovarian cancer histologically indistinguishable
from USPC, have been previously shown to identify
cancer patients who do not respond to chemotherapy [16].
Our results showing high levels of IL-6 secretion by
USPC, a variant of uterine carcinoma notorious for its
high resistance to chemotherapy and its aggressive
biologic behavior, are consistent with these findings. This
hypothesis is further supported by the recent demonstra-
tion that IL-6 promotes the resistance of tumor cells to
chemotherapeutic agents through the activation of the p38
mitogen-activated protein kinase (MAPK) signaling path-
way [19,23]. Of interest, the induction of MAPK signal-
ing pathway by IL-6 has been shown to require HER2/
neu expression [24], a growth factor receptor recently
identified to be highly up-regulated in the majority of
USPC [25] and correlated with poor prognosis in USPC
[26]. Taken together, these data suggest that high levels of
IL-6 gene expression and protein secretion in USPC may
S. Bellone et al. / Gynecologic Oncology 98 (2005) 92–98 97be associated with the HER2/neu signaling cascade and
may promote the resistance of USPC cells to cytotoxic
agents.
When IL-6 levels were quantified in the serum of
endometrial cancer patients, we found significantly higher
concentrations of IL-6 in both USPC and EC patients, when
compared to the levels found in healthy control women or
patients harboring benign gynecologic disease. However,
USPC patients had on average 6.1-fold higher levels of IL-
6 when compared to EC. These data are consistent with
our in vitro results on IL-6 secretion in primary USPC,
which were found to secrete significantly higher levels of
IL-6 when compared to primary EC. It is worth noting
that, in our series of USPC patients, all of whom were
surgically staged by a gynecologic oncologist, the striking
majority were found to harbor advanced disease. Thus,
although most of our patients were considered clinical
stage I and up-graded only at the time of the compre-
hensive surgical staging laparotomy, it is possible that the
elevated levels of IL-6 found in this work may reflect a
bias related to the high number of patients with advanced
disease. Only two patients had surgically confirmed early
stage disease. One of them, however, was found to have an
elevated level of IL-6. Larger studies including more
patients harboring surgically confirmed early stage USPC
disease will be necessary to exclude this hypothesis. It is
important to point out, however, that because of the
propensity of USPC to rapidly manifest extrauterine disease
(i.e., positive lymph node metastases or spreading to the
abdominal cavity), the USPC series reported here seems most
representative of the advanced stage disease commonly
detected in comprehensively surgically staged USPC patients
[5,27–29].
Tumor-antigen pulsed dendritic cells (DC) [i.e., the most
potent professional antigen presenting cells (pAPC) known
in humans for triggering the induction of an antigen-specific
immune response] (for review see [30]) have recently been
reported by our group to induce the generation of tumor-
specific cytotoxic T cells in patients harboring advanced
USPC in vitro [21]. These data, combined with the
promising preliminary clinical data reported in other human
malignancies when DC-based vaccinations have been used
to induce anti-tumor immunity [31–36], have generated
widespread interest in the use of these cells as a novel,
potentially effective, immunotherapeutic approach for the
treatment of residual/resistant USPC after standard surgical
and cytotoxic treatment. Of interest, tumor-derived IL-6 has
been reported to dramatically impair DC differentiation and
maturation and convert DC into suppressive antigen-
presenting cells capable of inducing tumor-specific T cell
tolerance [37, 38]. These data combined with our present
findings suggest that high IL-6 secretion by USPC may
create a highly immunosuppressive microenvironment in
vivo and may represent an important mechanism exploited
by USPC for modulating host anti-tumor immune
responses.In conclusion, we showed the first evidence that IL-6 is
highly expressed in USPC and that high concentrations of
IL-6 are present in the serum of USPC patients. Taken
together, our results support the premise that IL-6 may play
a major role in the induction and progression of this
biologically aggressive subtype of endometrial cancer and
may represent one of the main mechanisms exploited by
USPC for modulating host anti-tumor immune responses
and causing resistance to cytotoxic agents. Finally, these
findings suggest that drugs used to inhibit IL-6 activity by
receptor antagonists, neutralizing antibodies, the expression
of IL-6, or the IL-6 signal transduction pathway may
potentially be highly beneficial in USPC patients.Acknowledgments
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